It won the FDA's approval in May 2022 for the treatment of type 2 diabetes, for which tirzepatide is being marketed under the brand name Mounjaro. Lilly is also developing tirzepatide as a weight-loss treatment, for which the company's rolling submission to the FDA is currently ongoing, according to its website. In October 2022, the FDA granted tirzepatide its Fast Track designation in this indication. Joining tirzepatide in Lilly's weight-loss arsenal is orforglipron, an investigational oral non-peptide agonist of the GLP-1 receptor. In June 2023, the company posted mid-stage data demonstrating that the candidate can cut 8.6% to 12.6% of participants' body weight after 26 weeks. In July 2023, Lilly dropped $1.93 billion to acquire Versanis and its weight-loss monoclonal antibody bimagrumab. Source: BioSpace